SCHEMBL3633494

SCHEMBL3633494

CC(C)(C)OC(=O)N(CC(=O)O)Cc1cc(F)cc(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.40
PPARG P37231 4/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
MAOB P27338 1/20 0.38
SSTR4 P31391 1/20 0.37
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
GYS1 P13807 2/20 0.35
CYP2C9 P11712 1/20 0.34
KCNH2 Q12809 1/20 0.34
KCNQ4 P56696 1/20 0.34
KCNQ5 Q9NR82 1/20 0.34
GRM2 Q14416 1/20 0.34
NR3C1 P04150 2/20 0.33
BACE1 P56817 1/20 0.33
CA14 Q9ULX7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13053344 0.86 HDAC3 (0.37) PPARAPPARGHDAC3HDAC1HDAC2
SCHEMBL2897902 0.86 HDAC3 (0.46) PPARAHDAC3HDAC1HDAC2NCOR2
SCHEMBL2834319 0.81 HDAC3 (0.55) HDAC3HDAC1HDAC2NCOR2CTSL
SCHEMBL31696741 0.80 HDAC3 (0.40) PPARAPPARGHDAC3HDAC1HDAC2
SCHEMBL19950236 0.79 CLK1 (0.45) CTSLCTSBCTSSGRM2
SCHEMBL24022834 0.77 ABCB1 (0.37) HDAC3HDAC1HDAC2NCOR2SSTR4
SCHEMBL3858652 0.77 HDAC3 (0.46) HDAC3HDAC1HDAC2NCOR2SSTR4
SCHEMBL7594665 0.77 HDAC3 (0.44) PPARAPPARGHDAC3HDAC1HDAC2
SCHEMBL3402058 0.77 SLC6A4 (0.37) PPARAPPARGHDAC3HDAC1HDAC2
SCHEMBL2258654 0.77 TAAR1 (0.47) HDAC3HDAC1HDAC2NCOR2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372859-B2 CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups Merck, Sharp & Dohme Corp. (US) 2013-02-12 US disclosed
US-8372859-B2 CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups Merck, Sharp & Dohme Corp. (US) 2013-02-12 US disclosed
US-8372859-B2 CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups Merck, Sharp & Dohme Corp. (US) 2013-02-12 US disclosed
US-20100292263-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS MERCK SHARP & DOHME LLC 2010-11-18 US disclosed
US-20100292263-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS MERCK SHARP & DOHME LLC 2010-11-18 US disclosed
US-20100292263-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS MERCK SHARP & DOHME LLC 2010-11-18 US disclosed
EP-2146715-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMATE AND UREA END GROUPS Merck & Co., Inc. (US) 2010-01-27 EP disclosed
WO-2008127584-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMATE AND UREA END GROUPS MERCK & CO., INC. (US) 2008-10-23 WO disclosed
WO-2008127584-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMATE AND UREA END GROUPS MERCK & CO., INC. (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292263-A1 CGRP RECEPTOR ANTAGONISTS WITH TERTIARY AMIDE, SULFONAMIDE, CARBAMITE AND UREA GROUPS CALCR, QRFPR, CALCRL PPARA 1546/4885PPARG 795/4885HDAC3 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.